|
|
Zymeworks and ALX Oncology to evaluate Zanidatamab + ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer
“In addition to broad anti-tumor activity, zanidatamab’s safety profile supports combination approaches with other therapeutics,” said Diana Hausman, M.D., Chief Medical Officer at Zymeworks. “Our collaboration with ALX Oncology and their CD47 blocker, ALX148, has the potential to further expand the opportunity for zanidatamab to provide benefit to a broader population of patients, including those with advanced HER2‑expressing breast cancer.”
|
MD Anderson and Obsidian Therapeutics to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL™) for solid tumors
“TIL therapy has emerged as a promising option for treating patients with solid tumors, though its widespread use today is limited by safety and efficacy challenges,” said Rodabe Amaria, M.D., associate professor of Melanoma Medical Oncology at MD Anderson. “We are pleased to work with Obsidian to advance their novel cytoTIL program, which has the potential to drive more durable treatment responses and expand TIL therapy to a broader group of our patients.”
|
|
|
Precision Bioscience cuts a research collaboration and licensing deal with Eli Lilly for its gene-editing platform ARCUS®
20th November 2020: Precision Biosciences (North Carolina) announced a research collaboration and exclusive license agreement with Eli Lilly worth up to $555M. Precision Bioscience has developed a versatile genome editing technology ARCUS®, derived from a highly specific natural genome-editing enzyme called I-CreI. Under the terms of this license agreement Precision will receive $100M upfront. Eli Lilly will also invest $35M in Precision stock. Future payments up to $420 million would include milestones and royalties on developed products.
"We look forward to working with Lilly to leverage our deep understanding of in vivo gene editing and experience with ARCUS to develop new therapies, including a potentially transformative treatment for Duchenne muscular dystrophy," said Derek Jantz, chief scientific officer and co-founder of Precision BioSciences.
|
|
Novartis forges $1.35B deal with Mesoblast over Remestemcel-L for acute respiratory distress syndrome (ARDS), including COVID-19
On 20th November 2020, Mesoblast announced a license and collaboration agreement with Novartis to advance their ARDS therapeutic product remestemcel-L. Remestemcel-L is a Phase 3 mesenchymal stromal cell (MSC) product of Mesoblast which is believed to control the cytokine storm associated with COVID-19 and other inflammatory conditions. Currently, the drug is being tested in a Phase 3 study for Covid-19-related ARDS in 300 patients, and the initial data will be available in early 2021. Under the agreement deal, Mesoblast will receive a $50M upfront payment including $25 million in equity, while Novartis will acquire an exclusive worldwide right to develop, commercialize and manufacture remestemcel-L for ARDS. Besides, Mesoblast will gain additional pre-commercialization milestone payments that could total $505 million and post-commercialization milestones up to $750 million.
“Our collaboration with Novartis will help ensure that remestemcel-L could become available to the many patients suffering from ARDS, the principal cause of mortality in COVID-19 infection. This agreement is in line with our corporate strategy to collaborate and partner with world-leading major pharma companies to maximize market access for our innovative cellular medicines.” - Silviu Itescu, CEO, Mesoblast.
|
|
Click here for mergers , aquisitions and more business news
|
|
|
Disclaimer
The editors take care to share authentic information. In case of any discrepancies please write to medness.newsletter@gmail.com
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Medness. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for Medness. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
|
|
|
|
|
|
|